Last reviewed · How we verify
NCT06642857
Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
trial testing Peripheral blood, tougue coating, saliva, and feces in Advanced Gastric Carcinoma in 150 participants. Currently enrolling.
1 February 2026
Quick facts
| Lead sponsor | Xiangdong Cheng |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 25 March 2024 |
| Primary completion | 1 February 2026 |
| Estimated completion | 1 February 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Peripheral blood, tougue coating, saliva, and feces
Conditions studied
- Advanced Gastric Carcinoma — all drugs for Advanced Gastric Carcinoma →
- Advanced Gastroesophageal Junction Adenocarcinoma — all drugs for Advanced Gastroesophageal Junction Adenocarcinoma →
Sponsor
Xiangdong Cheng — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Gastric Carcinoma or Advanced Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06642857
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Gastric Carcinoma
Currently open trials in the same condition.
- NCT06028737 — Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer · Phase 2, PHASE3 · recruiting
- NCT05969860 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer · Phase 2 · recruiting
- NCT05620732 — Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T · NA · recruiting
- NCT05226169 — Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC) · Phase 3 · recruiting
- NCT04491942 — Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin a · Phase 1 · active not recruiting
Other Xiangdong Cheng trials
Trials by the same sponsor.
- NCT07068516 — Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer · Phase 3 · not yet recruiting
- NCT06766305 — QL1706 Combined With SOX Used in Theperioperative Treatment · Phase 1, PHASE2 · recruiting
- NCT06610799 — Study of IBI363 in Patients with Advanced First-line Gastric Cancer · Phase 1 · recruiting
- NCT06614179 — A Pan-cancer Screening and Diagnosis Model Based on Abdominal CT Was Established · recruiting
- NCT06374901 — Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06642857 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiangdong Cheng
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06642857.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing